SciTech to Present at Biotech Showcase 2020 in San Francisco
GROSSE POINTE, Mich.: SciTech Development announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square. Earle Holsapple, President will be presenting SciTech's innovative ST-001 nanoFenretinide technology at Biotech Showcase as follows:
Date: Monday, January 13, 2020
Time: 11:15 AM (PST)
Room: Franciscan B
Venue: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco, CA
Qualified investors can register to attend Biotech Showcase for free.
ST-001 nanoFenretinide is a small-molecule cancer drug comprised of nanoparticle sized fenretinide in a patented combination with carefully selected phospholipids. SciTech's product pipeline includes nanoFenretinide formulations for the treatment for several cancer indications. The FDA has granted Orphan Drug Status for ST-001 nanoFenretinide in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
SciTech Development, LLC is a clinical stage oncology drug company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
